Neuraly Inc Advances NLY01 Phase 2 MS Trial
GAITHERSBURG, Md., United States – May 2026 Neuraly Inc. has announced that the first patient has been dosed in...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
GAITHERSBURG, Md., United States – May 2026 Neuraly Inc. has announced that the first patient has been dosed in...
